PRUNE, the human homologue of the Drosophila gene, is located in 1q21.3, a region highly ampli®ed in human sarcomas, malignant tumours of mesenchymal origin. Prune protein interacts with the metastasis suppressor nm23-H1, but shows impaired anity towards the nm23-H1 S120G mutant associated with advanced neuroblastoma. Based on these observations, we previously suggested that prune may act as a negative regulator of nm23-H1 activity. We found ampli®cation of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant ®brous histiocytomas (MFH) as well as in the less malignant liposarcomas. PRUNE ampli®cation was generally accompanied by high mRNA and moderate to high protein levels. The sarcoma samples expressed nm23-H1 mostly at low or moderate levels, whereas mRNA and protein levels were moderate to high in breast carcinomas. For the more aggressive sarcoma subtypes, 9/13 patients with PRUNE ampli®cation developed metastases. A similar situation was observed in all breast carcinomas with ampli®cation of PRUNE. Infection of NIH3T3 cells with a PRUNE recombinant retrovirus increased cell proliferation. Possibly, ampli®-cation and overexpression of PRUNE has the same eect in the tumours. We suggest that ampli®cation and overexpression of PRUNE could be a mechanism for inhibition of nm23-H1 activity that aect the development or progression of these tumours. Oncogene (2001) 20, 6881 ± 6890.
PRUNE, the human homologue of the Drosophila gene, is located in 1q21.3, a region highly ampli®ed in human sarcomas, malignant tumours of mesenchymal origin. Prune protein interacts with the metastasis suppressor nm23-H1, but shows impaired anity towards the nm23-H1 S120G mutant associated with advanced neuroblastoma. Based on these observations, we previously suggested that prune may act as a negative regulator of nm23-H1 activity. We found ampli®cation of PRUNE in aggressive sarcoma subtypes, such as leiomyosarcomas and malignant ®brous histiocytomas (MFH) as well as in the less malignant liposarcomas. PRUNE ampli®cation was generally accompanied by high mRNA and moderate to high protein levels. The sarcoma samples expressed nm23-H1 mostly at low or moderate levels, whereas mRNA and protein levels were moderate to high in breast carcinomas. For the more aggressive sarcoma subtypes, 9/13 patients with PRUNE ampli®cation developed metastases. A similar situation was observed in all breast carcinomas with ampli®cation of PRUNE. Infection of NIH3T3 cells with a PRUNE recombinant retrovirus increased cell proliferation. Possibly, ampli®-cation and overexpression of PRUNE has the same eect in the tumours. We suggest that ampli®cation and
Introduction
Sarcomas comprise a large, heterogeneous group of tumours of mesenchymal origin (Enzinger and Weiss, 1995) . Although infrequently occurring, these tumours have been widely studied at the molecular level, and this has provided insight into mechanisms of importance for tumour development in general. Notably, ampli®cation and overexpression of MDM2 and CDK4, representing alternative pathways for inactivation of the tumour suppressors p53 and pRb, were ®rst described for this group of tumours (Oliner et al., 1992; Khatib et al., 1993) .
Comparative genomic hybridisation (Kallioniemi et al., 1992) revealed novel ampli®ed regions that seem to be important for the development of sarcomas, in particular 1q21-q22 (Forus et al., 1995a,b; Szymanska et al., 1996) . A variety of solid tumours show ampli®cation of 1q21-q22, e.g. 70 ± 80% of hepatocellular carcinomas and 25 ± 30% of ovarian cancers (Tapper et al., 1998; Wong et al., 1999; Zimonjic et al., 1999) . Although gain of the whole long arm (1q) is most frequent in breast cancers, local ampli®cation aecting 1q21-q22 has been observed (Tirkkonen et al., 1998) . Studies of renal clear cell and hepatocellular carcinomas revealed a higher frequency of 1q21-q23 gains in metastatic tumours (Gronwald et al., 1997; Qin et al., 1999) , and gains of the 1q21-q25 region have been associated with short overall survival in high-grade osteosarcomas and neuroblastomas Tarkkanen et al., 1999) .
We have characterised the 1q21-q22 amplicon in sarcomas by analysing copy numbers of known genes and genomic clones (Forus et al., 1998) . None of the genes showed the high copy numbers and frequent ampli®cation expected for a candidate gene, but two partly overlapping YACs (Yeast Arti®cial Chromosomes) located proximal to the S100-cluster (Marenholz et al., 1996) were frequently ampli®ed.
Recently, the human homologue of the Drosophila Prune gene was cloned (Ban® et al., 1996; Timmons and Shearn, 1996; Volorio et al., 1998; Reymond et al., 1999) . PRUNE is located on chromosome 1q21.3, in the ampli®ed chromosomal region covered by the two YACs. Mutation of Drosophila Prune reduces the red pigment and changes the colour of the eye to a brownish purple (Lindsley and Zimm, 1992) . The metabolic defects in the Prune¯y do not aect viability or fertility, however, the homo-or hemizygous Prune mutant is lethal in the presence of a single copy of a gain-of-function mutation in the abnormal wing disc gene (awd), dubbed`Killer-of-Prune' (awd K-pn ). Thē ies die at the third larval instar stage, developing melanotic (pseudo) tumours (Orevi and Falk, 1975; Biggs et al., 1988) .
The human protein nm23-H1 is one of the human homologues of Drosophila awd (Biggs et al., 1990; Leone et al., 1991 Leone et al., , 1993 . Eight dierent genes of this family have been identi®ed in humans (Lombardi et al., 2000) , and their expression is linked to suppression of tumour metastasis, dierentiation, apoptosis, proliferation and DNA mutation (de la Rosa et al., 1995) . NM23-H1 and -H2 are nucleoside diphosphate (NDP) kinases, and metastasis suppression was observed in several tumour cell lines transfected with nm23-H1 (Leone et al., 1991; Russell et al., 1998) . Recently, it was reported that increased nm23-H1 expression, induced by an inhibitor of DNA methylation, reduced cell motility but had little eect on cell proliferation (Hartsough et al., 2001) . Other investigators have reported that nm23-H1 may also play a role in the regulation of cell structure and shape, as it has been shown to be a constituent of the centrosome (Roymans et al., 2001) .
In colon, breast, gastric and ovarian carcinomas, as well as in melanomas, an inverse association between nm23-H1 expression and metastasis has been found (Hennessy et al., 1991; Florenes et al., 1992; Martinez et al., 1995; Srivatsa et al., 1996; Muller et al., 1998) . Nevertheless, the opposite has also been observed: in neuroblastoma, high levels of a mutated NM23-H1 mRNA was often associated with advanced stages of disease and poor patient survival (Chang et al., 1994) , and in sarcomas, nm23-H1 expression was found to increase with the metastatic potential for some tumours, but some aggressive cases also showed loss of expression (Royds et al., 1997) .
We have shown that prune protein binds nm23-H1 (Reymond et al., 1999) and nm23-H2 (D'Angelo et al., unpublished results) both in vitro and in vivo. Moreover, prune interacts with the nm23-H1 mutant P96S, that mimics the activity of the awd K-pn mutant, but shows an impaired anity towards the gain-offunction mutant nm23-H1 S120G associated with advanced neuroblastoma (Reymond et al., 1999) . We suggested that prune may act as a negative regulator of nm23-H1 activity, and the gene is therefore an interesting candidate for the 1q21-q22 ampli®cations. We have analysed a panel of sarcomas with 1q21-q22 ampli®cation and some advanced breast carcinomas for PRUNE ampli®cation, and correlated this to mRNA and protein expression levels of both prune and nm23-H1. PRUNE ampli®cation and/or overexpression was found in tumours that expressed nm23-H1, and was frequent in aggressive, metastasising tumours as well as in tumours of borderline malignancy. This is similar to what has been reported for ampli®cation of MDM2 in sarcomas (Forus et al., 1993; Berner et al., 1996; Pedeutour et al., 1999) . These results could suggest that for some tumours, inactivation of nm23-H1 by ampli®cation and/or overexpression of PRUNE may be important for development, and in other tumours, it will aect the progression or the metastatic potential.
Results

PRUNE amplification
PRUNE copy numbers were analysed in a panel of sarcomas where the 1q21 ampli®cation status has been previously de®ned (Forus et al., 1995a (Forus et al., , 1998 Simons et al., 2000) . Among the 19 samples analysed, 16 showed moderate ampli®cation (3 ± 9 signals) of PRUNE in more than 50% of the cells, and of those, ®ve showed high-level ampli®cation (510 signals) in 25 ± 60% of the cells (Figure 1 ). In two additional samples, ampli®cation of PRUNE was moderated, and in one, copy numbers were normal.
Five of the six primary cases of advanced breast carcinomas showed moderate ampli®cation of PRUNE, the last one had normal copy numbers (Figure 1 ). Ampli®cation was found in 33 ± 83% of the nuclei. For all samples with ampli®cation, the average copy number of PRUNE was always considerably higher than the average copy numbers of centromere 1. mRNA expression of PRUNE and NM23-H1 Expression of PRUNE was examined in 17 sarcoma samples (LMS14 and MFH 49 were not available and from LS2, LS6, LS9 data is not shown) by Northern blot analysis. In general, samples with moderate or high ampli®cation of the gene showed moderate to high mRNA expression ( Figure 2 and Table 1) , with a few exceptions: MFH25, which showed normal copy numbers, showed very high expression levels of PRUNE, in MFH9 and LMS2x, expression was low or absent, although the gene was ampli®ed in both samples. The latter could be an artefact due to the small amount of RNA present on the blot (not shown). Overall, the well dierentiated liposarcomas (grade 1) showed low mRNA expression of PRUNE compared to the high mRNA expression levels observed for the more aggressive sarcoma (grade 3 ± 4; LMS, MFH and MS).
Five of the six breast cancer samples showed high expression levels of PRUNE, including Ma15, which showed normal copy numbers of the gene (Table 1 and Figure 2 ). Only Ma51 showed low to moderate expression. The breast carcinomas with high level of PRUNE mRNA were classi®ed as moderate and highgrade tumours.
Expression of NM23-H1 was also variable. Most sarcoma samples showed low mRNA levels, and moderate to high expression levels were only detected in LMS14 and MFH3x. In contrast, ®ve out of six breast cancers showed moderate to high expression levels of NM23-H1 (Table 1 and Figure 2 ), and only Ma51 showed low expression levels.
prune and Nm23-H1 protein expression
Expression of prune and nm23-H1 proteins was examined by immunohistochemistry on paran embedded tissues from 14 of the samples that were analysed by FISH, and in 16 additional LS and MFH cases (Table 1 and Figure 3b ,c). In sarcomas, samples with increased copy numbers of PRUNE in more than 40% of the nuclei generally showed moderate to high expression of the protein, with some exceptions: in MS8x, LMS2x and LMS15, no protein could be detected, and in LS3x, only very low levels. The lack of protein signal was due to improper ®xation of the tissues (NR in Table 1 ). In general, most of the LS and MFH cases examined showed moderate to high levels of prune, and more variable expression levels of nm23-H1.
The ®ve breast cancer samples with ampli®cation of PRUNE had low or moderate expression of the protein, although mRNA levels were generally high. Expression of nm23-H1 protein was moderate to high in most of the sarcoma and breast carcinoma samples, except for Ma215, where no expression could be detected (Table 1 and Figure 3 ). Copy numbers of PRUNE on interphase nuclei from frozen tissue and paran embedded tissue. Signals were detected by avidin conjugated Cy3 (red), anti-digoxygenin-labelled FITC (green) or streptavidin-conjugated FITC (green). All these samples showed ampli®cation of PRUNE relative to centromere 1, but copy numbers were variable Figure 2 Northern analyses of PRUNE and nm23-H1-expression. Representative Northern blot showing expression of nm23-H1 and PRUNE in 14 sarcomas and two mammary carcinomas from which RNA was available. A probe for 18S rRNA was used as loading control. Quantitation of expression levels is shown in Table 1 . OHS is an osteosarcoma cell line that was included as a loading control here. This cell line was not examined for PRUNE ampli®cation or prune/nm23-H1 protein expression
Cellular proliferation assay
To further understand the role of prune overexpression we have tested its cell proliferation activity in retroviruses infected NIH3T3 cells. Prune recombinant retrovirus increases cellular proliferation fourfold compared to the control (Figure 4a) . Similarly, almost twofold increase in proliferation (measured after 48, 72 and 96 h) was observed in transient transfection experiments (48 h post transfection) see Figure 4c .
The same is true for a positive control gene (RET/ PTC3, Santoro et al., 1994) used in the assay (not shown).
Discussion
Ampli®cation of 1q21-q22 is among the most common chromosomal aberrations in a variety of human cancers. In some tumour types, this aberration is more This patient also suered from cancer in the lung and kidneys Prune amplification in sarcoma A Forus et al frequent in metastatic than in primary lesions, associated with short overall survival Tarkkanen et al., 1999) , and/or chemotherapy resistance (Kudoh et al., 1999) . These ®ndings suggest that possible target genes could be involved in metastasis-related processes, for instance by inhibiting possible metastasis suppressor proteins, or in mechanisms of drug resistance. It has been suggested that prune, a putative phosphoesterase, may act as a negative regulator of the NDPKinase and putative metastasis suppressor nm23-H1. Prune is ubiquitously expressed in human adult tissues (Reymond et al., 1999) , while nm23-H1 expression is higher in normal than neoplastic tissues. Accordingly, one would expect that the expression level of prune and nm23-H1 is balanced and tightly regulated in normal cells. In neoplastic tissues, however, we propose that ampli®cation and overexpression of PRUNE could shift this balance and abrogate the possible regulatory function of nm23-H1. To be signi®cant, this would require co-expression of the two proteins. Such a mechanism could be comparable to the eect of ampli®cation of MDM2 and CDK4/CCND1 on p53 and pRb1, respectively. Increased expression of these oncoproteins, caused by increased copy numbers of the respective genes, has been shown to inhibit the function of the two tumour suppressors (Momand et al., 1992; Oliner et al., 1992; Khatib et al., 1993; He et al., 1995; Pilotti et al., 1998) .
We found ampli®cation of PRUNE at various levels in 18 out of 19 sarcoma samples. This is the very ®rst indication that ampli®cation and increased expression of an oncogene could be a mechanism for inhibition of nm23-H1 activity. PRUNE is also the ®rst candidate gene for the 1q21-q22 amplicon in sarcoma that may aect a possible suppressor of metastasis or proliferation. In the more aggressive sarcoma types, LMS, MFH and MS, PRUNE ampli®cation was generally accompanied by moderate to high mRNA levels, and corresponding protein levels. All these samples expressed nm23-H1 mRNA and protein, mostly at low or moderate levels. Thirteen of the patients in this group showed ampli®cation of PRUNE, and among those, nine developed metastases, and seven of those died of cancer. For the patients with an unknown copy number of PRUNE (16 LS and MFH cases) there was no clear correlation between prune and/or nm23-H1 protein expression and prognosis. Nevertheless, the four patients that developed metastases and died all showed moderate to high expression levels of prune, and low to moderate levels of nm23-H1. The number of patients analysed is too low to draw any conclusion on the association of PRUNE ampli®cation and overexpression with metastasis events or disease outcome, but it is remarkable that the expression levels of the gene is generally higher in aggressive tumours than in the relatively benign well-dierentiated liposarcomas (WDLPS).
Likewise ®ve out of six breast carcinomas showed moderate ampli®cation of PRUNE. In these tumours, mRNA levels of both PRUNE and NM23-H1 were generally high, although protein levels were low to moderate for prune and moderate to high for nm23-H1. Some reports have suggested an association Table 1 between nm23-H1 negativity and poor prognosis (Royds et al., 1993) , whereas other reports show that nm23-H1 expression increases in breast carcinoma tissue (Sastre-Garau et al., 1992) , thus, the results are con¯icting. It would be interesting to examine how ampli®cation and overexpression of PRUNE correlates with nm23-H1 expression and prognosis in a larger series of breast carcinomas and sarcomas of dierent grading, since we could not ®nd an unequivocal correlation due to the modest number of samples studied here.
In tumours with expression of nm23-H1 and ampli®cation of PRUNE we speculate that the increased levels of prune may interfere with the proposed suppressor activities of nm23-H1. Accordingly, one would expect to ®nd PRUNE ampli®ca-tion mainly in tumours that express a normal nm23-H1, and tumours with the nm23-H1-S120G mutation would probably not have a selective advantage from PRUNE ampli®cation since this mutant protein has a diminished anity towards prune (Reymond et al., 1999) . This model would also explain why some tumours behave aggressively despite their high levels of (normal) nm23-H1, as has been reported for instance in gastric carcinomas (Muller et al., 1998) .
The ®nding that PRUNE is ampli®ed and overexpressed both in aggressive tumours and tumours of borderline malignancy is similar to what has been reported for MDM2 in sarcomas (Forus et al., 1993; Berner et al., 1996; Pedeutour et al., 1999) . For instance, MDM2 is ampli®ed and over-expressed in almost all WDLPS cases reported to date, although these tumours are of borderline malignancy, and hardly ever metastasise. Furthermore, although one important role for mdm2 over-expression is to inactivate p53, there is no clear correlation between MDM2 ampli®cation and tumour aggressiveness.
At present, we have no evidence that prune inhibits the suggested anti-metastatic activity of nm23-H1. However, we show that (over)expression of prune increases proliferation in NIH3T3 cells. Possibly, the ampli®cation and overexpression of the gene may have a similar eect in the tumours. This would explain why ampli®cation of the gene could provide a selective advantage also in the relatively benign WDLPS, which In the upper and the bottom panel 5000 cells/well and 10 000 cells/well were analysed, respectively. Time points have been scored for 12 independent wells (MTS assay) corresponding to two independent replica clones (#1, #2). (d) Western blot analyses. NIH3T3 transfected protein extracts (6 mg/lane) were analysed 96 h after transfection by using a-Prune and a-FLAG Abs at 1 : 5000 and 1 : 6000 dilution (West Femto substrate) respectively are tumours that tend to recur, but hardly ever metastasise. However, we do not know at present if this function is regulated by nm23-H1, or via other mechanisms. Furthermore, the data correlating low activity of nm23-H1 to tumour aggressiveness are rather con¯icting, and the exact role of nm23-H1 as a metastasis suppressor is not clear. There are several reports that link nm23-H1 activity to cell growth and proliferation. In some cases, decreasing levels of nm23-H1 is associated with increased proliferation , whereas in other studies, the opposite has been shown . Interestingly, Hartsough et al. (2001) recently showed that increased Nm23-H1 expression as induced by DNA methylation inhibitors reduced cell motility, thus suggesting a direct function for Nm23-H1 in one aspect of metastasis. We suggest that for some tumours, inactivation of nm23-H1 by ampli®cation and/or over-expression of PRUNE may be important for development, and in other tumours, it will aect the progression or the metastatic potential.
Recently, Subramanian et al. (2001) reported that the Epstein-Barr virus encoded protein EBNA-3C interacts speci®cally with nm23-H1, and that this interaction reversed the ability of nm23-H1 to suppress migration of Burkitts lymphoma and breast carcinoma cells. This is the ®rst evidence that a DNA tumour virus may target a cellular protein associated with metastasis. Furthermore, Tseng et al. (2001) have reported that an interaction between Rad, a novel Ras-related GTPase, and nm23-H1 may regulate growth and tumorigenicity of breast cancer cells. Since nm23-H1 seems to be involved in a variety of cellular processes, inhibition of the nm23-H1 protein may involve various oncoproteins that target dierent nm23-H1 protein functions. It will be important to identify other nm23-H1 interacting and regulating proteins in order to fully understand the role of this protein in tumorigenesis and metastasis.
The 1q21-22 region is large and gene rich (Marenholz et al., 1996; White et al., 1999) , and contains several genes with a suggested role in tumour development or progression. The other major amplicon in sarcomas, 12q13-15, contain at least three candidate genes with a proposed role in tumour development, MDM2, HMGIC and CDK4 (Momand et al., 1992; Oliner et al., 1992; Forus et al., 1993; Khatib et al., 1993; Berner et al., 1996 Berner et al., , 1997 . The frequency of ampli®cation of the dierent genes may vary among dierent tumour types. It is quite likely that PRUNE ampli®cation, in a similar way, may be particularly important in some sarcoma subtypes, whereas other genes may be the driving force in other tumours.
Materials and methods
Material
Nineteen sarcomas were ®rst analysed by FISH and Northern analysis: three leiomyosarcomas (LMS), six liposarcomas (LS), nine malignant ®brous histiocytomas (MFH) and one malignant peripheral nerve-sheath tumour (malignant Schwannoma, MS). All tumours except for one were previously analysed by CGH (Forus et al., 1995a; Simons et al., 2000) . Six primary mammary carcinomas (Ma) from patient with advanced stage were included. The tissues were collected immediately after surgery, snap-frozen in liquid nitrogen and stored at 7808C. Fourteen of the sarcomas, the six Ma samples and 16 additional paran embedded LS and MFH (tissue array) samples were analysed by immunohistochemistry. All the tumours were classi®ed according to the WHO International Histological Classi®cation of Tumours (Weiss, 1994) .
Fluorescent in situ hybridisation (FISH) to interphase nuclei
Preparation of interphase nuclei from frozen tissues and cell lines was done as described (Forus et al., 1998) . One of the samples, LMS14 was available only as paran embedded tissue. Preparation of the sections was done by standard procedures.
Probes PAC 279H19, containing the human PRUNE gene, was from the human PAC library RPCI-5 pools. The centromere 1 probe was a biotin-labelled D1Z5 a-satellite (P5001-B.5, Oncor, Gaithersburg, MD, USA).
Preparation of probes DNA from 279H19 was labelled with biotin-14-dATP or digoxygenin-11-dUTP (BoehringerMannheim, Germany) by nick translation. For each hybridisation, 200 ± 500 ng of labelled DNA was prehybridised with 50 ± 100-fold excess of human Cot-1 DNA. The probes were denatured at 808C for 10 min, snap-cooled on ice and pre-hybridised at 378C for 30 ± 60 min. The centromere 1 probe was used as recommended by the manufacturer.
FISH hybridisation to interphase nuclei Slides were treated as described (Forus et al., 2001) , hybridisation and washes were according to standard procedures. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-digoxygenin (Boehringer Mannheim, Germany) followed by FITC-or ALEXA 488-labelled donkey anti-sheep (Molecular Probes, Leiden, The Netherlands) was used for detection of digoxigenin, andavidin-conjugated Cy3 (Amersham Life Science, Little Chalfont, UK) for detection of biotin.
FISH hybridisation to paran sections Slides were treated as described (Kononen et al., 1998) . Detection of signals was done by tyramide ampli®cation (TSA-Indirect kit for ISH, NEN, Boston, MA, USA) followed by a streptavidine-FITC antibody (NEN, Boston, MA, USA) (Forus et al., 2001) .
Evaluation of results Hybridised slides were examined visually using a Zeiss Axioplan microscope equipped with appropriate ®lter for exitation of DAPI, DAPI/FITC, DAPI/ Rhodamine (Cy3), and DAPI/FITC/Rhodamine(Cy3). For each probe, the number of hybridisation signals was counted in at least 150 nuclei per slide.
Prune retrovirus production and cellular proliferation assay pBABE puro-PC3 vector was modi®ed to include a FLAG epitope at the carboxy-terminal region of the protein and an SP6 promoter and primer site at the 3' terminus in the poly-linker sequence at the EcoRI site. The vector was used to subclone the entire full-length PRUNE cDNA and used in transient transfection of BOSC 23 ecotropic retroviruses cells as described (Pear et al., 1993) . High titer retrovirus supernatant was collected and used to infect NIH3T3 cells lines, a generous gift from Dr Mario Chiariello (UniversitaÁ degli Studi Federico II, Naples, Italy). After 4 days on puromycin (2 mg/ml) selection the cells were tested by a cellular proliferation and viability assay`MTS protocol' (Cell-Titer 96 TM AQ ueous proliferation assay-Promega). Cells were plated in a 96 well plate at concentrations ranging from 2.5, 5 and 10610 3 cells per well and assayed after 48 h. A colorimetric reaction was performed after incubation of the cells for 2 h at 378C measuring the absorbance (O.D.) at 490 nm using a Packard 96-well reader spectrophotometer. The results presented are the mean of four replicate assay series.
Transient transfection and cellular proliferation assay in NIH3T3 cells
1610
6 NIH3T3 cells were transfected by Lipofectamine reagent (Gibco-BRL) with 10 mg of pCDNA vector containing PRUNE cDNA-FLAG gene under a CMV promoter. After 48 h, transfected cells were plated in a 96 well plate and measured by MTS protocol (48, 72 and 96 h later).
Northern analyses
RNA expression levels were analysed by Northern blot analysis. Total cellular RNA was isolated from frozen tissue or cell lines, electrophoresed and blotted onto membranes essentially as described (Forus et al., 1993) . Quantitation of signal intensities was carried out by two-dimensional densitometry on a laser densitometer (Molecular Dynamics), and expression levels were calculated using the ImageQuant analysis software. A PRUNE cDNA clone and a speci®c cDNA probe for nm23-H1 as described (Reymond et al., 1999) were sequentially hybridised to the ®lter. The net signal values were corrected for uneven loading by calibration relative to signals from an 18S-oligonucleotide control probe. Expression levels were grouped as follows: No expression (0), weak (1), moderate (2) and high (3).
Immunohistochemistry
Construction of a tissue array Thirty of the sarcoma samples have been included in a tissue-array (Forus and Kononen, unpublished) and protein analyses of these samples was done using this array. All the samples were from archived formalin-®xed, paran embedded material. Two tissue cylinders (0.6 mm) were punched from representative tumour areas on each tissue block, and both samples were evaluated in the protein analyses. The construction of the arrays was done as described previously (Kononen et al., 1998; Schraml et al., 1999) . For the remaining samples, 4 m sections were prepared from formalin-®xed, paran embedded material after standard procedures.
Production of prune antibodies The entire full-length PRUNE cDNA and almost two thirds of the entire cDNA was sub-cloned in both pMaltose and PGEX4X plasmid to produce E. Coli fused protein (inducible expression systems) respectively. E. Coli competent cells were transformed and induced by IPTG for 3 h at 378C. Cells were harvested and lysed with low stringent detergent solution, and protein puri®cation was performed as described (New England Biolabs Inc.; Pharmacia Biotech). Columns with amylose and glutathione-derived resin were used to further purify the fused protein, and a total of 1.3 mg of pure recombinant protein was injected in rabbits to obtain polyclonal antibodies. The antibodies were puri®ed according to manufacturer's protocols. Western blotting (Figure 3a) and immuno-¯uorescence analysis on paran-embedded human tissue sections were used to determine the anity and speci®city of the prune polyclonal antibody.
Western blotting Standard procedures were followed. The prune polyclonal antibody was used at 1 : 500 dilution. The control, anti-FLAG monoclonal antibody M2 Ab (Sigma), was used at 1 : 4000 dilution. ECL detection system (Amersham), West Femto substrate (Pierce) and PVDF transfer membranes (Millipore) were used according to manufacturer's protocols.
Antibody staining All IHC analyses were done on paran sections from individual samples or the tissue array. The ABC procedure was used for immunohistochemistry (VEC-TASTAIN from Vector, Vector Laboratories, Inc). The monoclonal antibody anti-NDP kinase:nm23-H1, clone NM301 (from Santa Cruz USA) was used at 1 : 25 dilution. The prune polyclonal antibody was used at 1 : 300 dilution and the monoclonal anti-vimentin antibody (clone Vim 3B4, Boehringer-Mannheim) was used at 1 : 300 dilution. Colorimetric reaction was performed by using DAB (Vector, Vector Laboratories, Inc). Microwave pretreatment was used for nm23-H1 and vimentin detection for 15' at 908C in 10 mM NaCitrate pH6. The primary antibody was omitted for negative controls. Positive controls included sections from tissues known to be positive. The controls gave satisfactory results.
Evaluation of results
We have observed nm23H1 protein with a prevalent nuclear localisation and with some cytoplasmic staining, whereas prune immunoreactivity was mainly cytoplasmic and in few cases nuclear as already described by Reymond et al. (1999) . Tumours were considered positive if at least 10% of the tumour cells were stained. Signal intensity was grouped as follows: Negative (0, expression in 510% of the cells), weakly positive (1), moderately positive (2) and strong (3).
